Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
Portfolio Pulse from
Capricor Therapeutics' cell therapy, deramiocel, is under priority FDA review for treating Duchenne muscular dystrophy cardiomyopathy.
March 04, 2025 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' investigational cell therapy, deramiocel, is under priority FDA review for treating Duchenne muscular dystrophy cardiomyopathy, potentially accelerating its market entry.
The FDA's priority review of Capricor's deramiocel suggests a significant step towards potential approval, which could positively impact CAPR's stock price due to the anticipation of market entry and revenue generation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100